Cargando…
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
Autores principales: | Abuelgasim, Khadega A., Alzahrani, Mohsen, Alsharhan, Yousef, Khairi, Moataz, Hommady, Mohammed, Gmati, Giamal, Salama, Hind, Ali, Osama, Alahmari, Bader, Masuadi, Emad M., Alaskar, Ahmed, Alhejazi, Ayman, Damlaj, Moussab |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760548/ https://www.ncbi.nlm.nih.gov/pubmed/30700792 http://dx.doi.org/10.1038/s41409-019-0454-z |
Ejemplares similares
-
Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era
por: Abuelgasim, Khadega A, et al.
Publicado: (2021) -
Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review
por: Abuelgasim, Khadega A., et al.
Publicado: (2020) -
Middle East Respiratory Syndrome (MERS) Infection in Hematological and Oncological Patients: A Case Series from a Tertiary Care Center in Saudi Arabia
por: Alaskar, Ahmed, et al.
Publicado: (2019) -
Outcome of Middle East Respiratory Syndrome (MERS) in hematology and oncology patients: A case series in Saudi Arabia
por: Alaskar, Ahmed, et al.
Publicado: (2021) -
Reducing Central Venous Catheter Use in Peripheral Blood Stem Cell Donation: Quality Improvement Report
por: Ghazi, Samer, et al.
Publicado: (2017)